Trial Profile
The effect of anagliptin on blood glucose and serum lipids in Patients with type 2 diabetes mellitus
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 30 Jun 2022
Price :
$35
*
At a glance
- Drugs Anagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 26 Jun 2022 According to UMIN, Date of closure to data entry and Date analysis concluded is 30 June 2022.
- 26 Jun 2022 Status changed from recruiting to discontinued.
- 26 Jun 2018 Status changed from not yet recruiting to recruiting.